Delic Holdings Corp. (DELCF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerDelic Holdings Corp. (DELCF) trades at $0.0002. Delic Holdings Corp. operates in the psychedelic wellness industry, providing ketamine infusion treatments through clinics and educational content via various digital platforms. Sector: Communication services.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for DELCF: DELCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Delic Holdings Corp. (DELCF) Media & Communications Profile
Delic Holdings Corp. is a Canadian-headquartered entity operating in the psychedelic wellness sector, offering ketamine infusion treatments across multiple clinics in the U.S. and Canada, alongside a suite of digital platforms for psychedelic culture education, news, and discourse, aiming to expand access and understanding of alternative mental health therapies.
What Is the Investment Thesis for DELCF?
Delic Holdings Corp. is positioned within the nascent yet expanding psychedelic wellness industry, characterized by increasing interest in alternative mental health treatments. The company's dual strategy of operating ketamine infusion clinics and developing extensive digital content platforms aims to capitalize on both direct patient care and public education. Its gross margin of 100.8% suggests efficient cost management relative to revenue, particularly in its service-oriented operations, which could be a significant value driver if revenue scales. The focus on developing intellectual property through research and development in cannabis and psychedelics represents a long-term growth catalyst, potentially leading to proprietary treatments or formulations. However, the company's extremely low market capitalization of $0.00 billion and a significant negative profit margin of -570.6% indicate substantial operational challenges and a need for sustainable revenue growth and profitability. Investors will be monitoring the company's ability to expand its clinic network, monetize its digital assets, and secure funding to support its ambitious growth initiatives in this evolving and highly regulated sector.
Based on FMP financials and quantitative analysis
DELCF Key Highlights
Market Capitalization: Delic Holdings Corp. currently holds a market capitalization of $0.00 billion, indicating its status as a micro-cap entity.
- Profitability: The company reported a profit margin of -570.6%, reflecting significant unprofitability in its current operational phase.
- Gross Margin: Delic Holdings Corp. achieved a gross margin of 100.8%, suggesting strong control over direct costs relative to its revenue, potentially driven by its service-based clinic operations.
- Employee Base: The company employs 116 individuals, with operations managed under the leadership of CEO Kevin Nicholson.
- Market Sensitivity: With a Beta of -0.03, the stock has historically shown very low correlation with the broader market movements, indicating a degree of independence from general market trends.
Who Are DELCF's Competitors?
DELCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ONFO Onfolio Holdings, Inc. | $0.86 | -5.41% | — | |
| NAMI Jinxin Technology Holding Company | $2.28 | -5.79% | $6.27M | — |
| SLE Super League Enterprise, Inc. | $5.30 | -2.21% | $8.98M | — |
| CCG Cheche Group Inc. | $5.35 | +0.75% | $12.6M | — |
| GETY Getty Images Holdings, Inc. | $0.08 | -6.98% | $33.5M | — |
| BODI The Beachbody Company, Inc. | $4.92 | +3.58% | $35.6M | 35 5-pillar |
| ZDGE Zedge, Inc. | $3.00 | +0.33% | $39.2M | 41 5-pillar |
| SEAT Vivid Seats Inc. | $3.52 | -7.85% | $39.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DELCF's Key Strengths?
Diverse business model combining clinical services (ketamine clinics) with extensive digital content and event platforms.
- Early mover in the emerging psychedelic wellness industry, establishing brand presence and operational footprint.
- Large existing content library (Reality Sandwich with ~10,000 pieces) providing a strong educational foundation.
- High gross margin of 100.8%, indicating efficient cost management relative to revenue, particularly in service delivery.
- Strategic focus on intellectual property development in cannabis and psychedelics for future growth.
What Are DELCF's Weaknesses?
Significant unprofitability, evidenced by a -570.6% profit margin, indicating substantial operational losses.
- Extremely low market capitalization of $0.00 billion, suggesting limited access to capital and market confidence.
- Listing on the OTC Other tier, which typically entails lower liquidity and less stringent disclosure requirements.
- Disclosure status is 'Unknown' for its OTC listing, potentially limiting investor access to critical financial information.
- Negative Beta of -0.03, while indicating low market correlation, could also reflect a lack of investor interest or market-specific drivers.
What Are the Key Risks for DELCF?
Financial-distress signal — its Altman Z-Score of -2.49 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant unprofitability, as evidenced by a -570.6% profit margin, indicates substantial operational losses that require ongoing funding.
- Challenges associated with its OTC Other listing, including limited liquidity, potential for price volatility, and difficulties in raising capital.
- Regulatory changes or restrictions impacting the psychedelic and cannabis industries could hinder operations or limit growth opportunities.
- Intense competition from larger, more well-funded pharmaceutical companies or healthcare providers entering the psychedelic wellness space.
- Difficulty in securing additional funding to support operations and growth initiatives given its current financial performance and market capitalization.
What Are DELCF's Competitive Advantages?
- Early-mover advantage in the nascent and rapidly evolving psychedelic wellness industry, establishing a presence in both clinical and media sectors.
- Diverse operational model combining direct patient care through ketamine clinics with extensive digital content and event platforms, creating a synergistic ecosystem.
- Proprietary content library of approximately 10,000 pieces on Reality Sandwich, serving as a comprehensive educational resource and attracting a dedicated audience.
- Established network of ketamine infusion treatment clinics across the U.S. and Canada, providing a physical footprint for therapeutic services.
- Focus on intellectual property development in cannabis and psychedelics, potentially leading to unique and defensible therapeutic innovations.
What Does DELCF Do?
Delic Holdings Corp. is a Vancouver, Canada-headquartered company operating in the burgeoning psychedelic wellness industry across the United States and Canada. The company's business model encompasses both direct medical treatments and extensive digital content platforms, positioning it as a multifaceted player in the evolving landscape of alternative mental health solutions. Delic operates a network of ketamine infusion treatment clinics, including two wholly owned and thirteen additional clinics, providing direct therapeutic services. These clinics offer a recognized treatment modality for various mental health conditions, leveraging the growing acceptance and research into psychedelic-assisted therapies. Beyond clinical operations, Delic Holdings Corp. has established a significant presence in the digital media and education space. It manages 'The Delic,' a creative platform dedicated to fostering public discourse around psychedelic culture, offering a forum for discussion and exploration. Complementing this, 'Meet Delic' organizes events designed to promote a wide array of topics, from safety and harm reduction to the integration of psychedelics in mental health, human performance, and medicine, engaging both experts and the public. The company's educational arm includes 'Reality Sandwich,' an online platform boasting approximately 10,000 pieces of content, including guides, news, and cultural insights related to psychedelics. Furthermore, 'Delic Radio' serves as a podcast platform, featuring discussions with experts on news, science, culture, medicine, current affairs, and policy within the psychedelic realm. This dual approach of clinical services and comprehensive media platforms underscores Delic Holdings Corp.'s strategy to promote access, education, and intellectual property development in the cannabis and psychedelic sectors.
What Products and Services Does DELCF Offer?
- Operates two owned ketamine infusion treatment clinics and thirteen additional ketamine infusion treatment clinics.
- Manages The Delic, a creative platform for public discourse on psychedelic culture.
- Organizes 'Meet Delic' events focusing on psychedelic topics like safety, mental health, and integration.
- Hosts Reality Sandwich, an online education platform with approximately 10,000 pieces of content on psychedelic guides, news, and culture.
- Produces Delic Radio, a podcast featuring expert discussions on psychedelic news, science, culture, medicine, and policy.
- Engages in research and development to develop intellectual property related to cannabis and psychedelics.
- Provides various medicines and treatments in the United States and Canada, primarily through its ketamine clinics.
How Does DELCF Make Money?
- Generates revenue from direct patient services through its network of ketamine infusion treatment clinics.
- Earns income from organizing 'Meet Delic' events, potentially through ticket sales, sponsorships, and exhibitor fees.
- Monetizes its digital content platforms (Reality Sandwich, The Delic, Delic Radio) through advertising, potential subscriptions, or sponsored content.
- Aims for future revenue generation through the development and potential licensing of intellectual property in cannabis and psychedelics.
- Leverages its media platforms to build brand awareness and drive traffic to its clinical services and events.
What Industry Does DELCF Operate In?
Delic Holdings Corp. operates within the 'Internet Content & Information' industry, a sub-sector of 'Communication Services,' but its core business is deeply intertwined with the emerging psychedelic wellness industry. This sector is characterized by a growing societal interest in alternative mental health treatments and the increasing scientific validation of psychedelics for therapeutic purposes. The competitive landscape includes other clinic operators, pharmaceutical companies investing in psychedelic research, and various media platforms focusing on health and wellness. Delic's strategy of combining direct treatment through ketamine clinics with extensive educational content platforms positions it uniquely. It aims to capture market share by both providing services and shaping public perception and understanding, differentiating itself from pure clinic chains or content providers. The broader market trend points towards increased decriminalization and medicalization of certain psychedelics, creating a potential growth runway for companies like Delic, albeit within a highly regulated and evolving environment.
Who Are DELCF's Key Customers?
- Individuals seeking ketamine infusion treatments for mental health conditions in the United States and Canada.
- Individuals interested in psychedelic culture, education, news, and harm reduction.
- Professionals and experts in the psychedelic and mental health fields attending 'Meet Delic' events.
- Researchers and developers interested in intellectual property related to cannabis and psychedelics.
- General public seeking information and discourse on alternative therapies and psychedelic science.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Delic Holdings Corp. operates in the Internet Content & Information industry within the Communication Services sector. It is headquartered in Vancouver, CA. The company is led by CEO Kevin Nicholson. DELCF has traded publicly since 2021.
Key Financial Metrics
Return on assets is -59.7%, showing how much profit it generates from its asset base. A current ratio of 1.13 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Delic Holdings Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.49 places it in the distress zone, a signal of elevated financial risk.
DELCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
DELCF Latest News
No recent news available for DELCF.
DELCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for DELCF.
Price Targets
Wall Street price target analysis for DELCF.
DELCF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for DELCF; grades run from A+ (80-100) to F (below 30).
Leadership: Kevin Nicholson
CEO
He is identified as the managing executive for the company's 116 employees, overseeing the strategic direction and operational execution of its diverse psychedelic wellness initiatives across clinics and digital platforms in North America. His role involves guiding the company's efforts in both direct patient care and public education within the evolving psychedelic and cannabis sectors.
Track Record: Key achievements and strategic decisions under Kevin Nicholson's leadership are not detailed in the provided information. His tenure has overseen the operation and expansion of Delic's ketamine infusion treatment clinics and the development of its various content and event platforms, aiming to establish a presence in the evolving psychedelic and cannabis wellness sectors. His leadership is focused on navigating the company through the nascent stages of this industry, balancing clinical services with educational outreach and intellectual property development.
DELCF OTC Market Information
Delic Holdings Corp. trades on the 'OTC Other' tier of the OTC market. This tier is typically for companies that do not meet the reporting requirements for OTCQX or OTCQB, or choose not to disclose comprehensive financial information. Unlike major exchanges such as the NYSE or NASDAQ, which have stringent listing standards for financial health, corporate governance, and disclosure, the OTC Other tier has minimal to no public disclosure requirements. This classification often signifies a higher risk profile for investors due to limited transparency and oversight, making it challenging to assess the company's financial standing and operational performance.
- OTC Tier: OTC Other
- Limited Transparency: Unknown disclosure status means investors may lack access to critical financial and operational information, hindering informed decision-making.
- Price Volatility: Low trading volume and wide bid-ask spreads can lead to significant and unpredictable price fluctuations.
- Limited Access to Capital: The OTC Other classification can make it challenging for the company to raise capital through traditional equity offerings, impacting growth and operational stability.
- Potential for Manipulation: Less regulatory oversight compared to major exchanges can expose the stock to higher risks of market manipulation.
- Difficulty in Exiting Positions: Low liquidity can make it difficult for investors to sell shares quickly without incurring substantial losses or affecting the share price.
- Verify any available financial statements and audit reports directly from the company or regulatory filings, if accessible.
- Research the background and track record of the management team beyond what is publicly stated.
- Thoroughly understand the company's business operations, revenue streams, and market position within the psychedelic wellness industry.
- Assess the regulatory environment in which the company operates and its compliance with relevant laws and licenses.
- Investigate the company's share structure, outstanding shares, and any potential dilution risks.
- Check for any ongoing litigation, regulatory actions, or past enforcement issues.
- Evaluate the company's ability to secure future funding and its cash burn rate given its profitability.
- Operation of multiple ketamine infusion treatment clinics (two owned, thirteen additional) indicates tangible physical assets and service delivery.
- Maintenance of several active digital content platforms (The Delic, Reality Sandwich, Delic Radio) demonstrates ongoing operational activity and content creation.
- Stated focus on intellectual property development through research and development suggests a commitment to long-term value creation.
- Headquarters in Vancouver, Canada, a recognized financial and business hub, provides a degree of corporate structure.
- Management of 116 employees indicates a functional organizational structure and ongoing operational scale.
DELCF Communication Services Stock FAQ
What does Delic Holdings Corp. do?
Delic Holdings Corp. operates in the psychedelic wellness sector, offering a dual approach to its market. The company provides direct medical treatments through its network of two owned and thirteen additional ketamine infusion treatment clinics across the United States and Canada.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information regarding CEO's detailed background and track record is limited in the provided source data, leading to generalized statements.
- Specific market sizes and timelines for growth opportunities were not explicitly provided in the source data, requiring some inference based on industry trends.
- The 'Unknown' disclosure status for OTC analysis limits the depth of assessment regarding financial transparency.